Total value in 2020: $223.14M (37 deals)

Deal title Receiving grant Awarding grant Grant amount ($M) Date

January

MDA to award Aavantibio funding for phase II clinical trial of a gene-replacement therapy for Friedreich ataxia Aavantibio Muscular Dystrophy Association $1.07 1/13/20
DoD to award contract to Adaptive for the development of Phagebank against multidrug-resistant and complicated infections Adaptive Phage Therapeutics Inc U.S. Department of Defense $10.00 1/8/20
CARB-X to award Antabio funding for the development of small-molecule candidate for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis patients Antabio SAS Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator $4.40 1/2/20
Biocorrx received additional funding from National Institute on Drug Abuse for BICX-102 against opioid use disorder Biocorrx Inc. National Institute on Drug Abuse $2.30 1/30/20
Duchenne UK to fund Catabasis to evaluate edasalonexent in non-ambulatory Duchenne muscular dystrophy trial Catabasis Pharmaceuticals Inc. Duchenne UK $0.60 1/8/20
USAMRAA to award Cellphire funding to develop dimethyl sulfoxide cryopreserved platelets against hemorrhage Cellphire U.S. Army Medical Research Acquisition Activity $29.25 1/15/20
Prevent Cancer Foundation to award Cleveland Clinic Foundation's funding to conduct research on gut microbiota metabolism of dietary compounds to prevent cancer Cleveland Clinic Foundation Prevent Cancer Foundation $0.10 1/30/20
CFF to award Crestone's funding to conduct preclinical development of anti-NTM therapeutics against nontuberculous mycobacteria infections Crestone Inc. Cystic Fibrosis Foundation Payment unspecified 1/13/20
Curevac received funding from Coalition for Epidemic Preparedness Innovations to develop mRNA-based vaccine against coronavirus nCoV-2019 Curevac AG Coalition for Epidemic Preparedness Innovations $8.30 1/31/20
Vinnova to award Follicum funding to develop peptide-based therapies for diabetes Follicum AB Vinnova $0.05 1/31/20
NIA to award Gladstone Institute funding to study the role of ApoE4 in Alzheimer's disease Gladstone Institute National Institutes of Health $4.80 1/30/20
CEPI to award Inovio funding for the development of INO-4800 vaccine against emerged strain of coronavirus (2019-nCoV) Inovio Pharmaceuticals Inc. Coalition for Epidemic Preparedness Innovations $9.00 1/23/20
Coalition for Epidemic Preparedness Innovations to award Inovio funding for the development of vaccine against coronavirus nCoV-2019 Inovio Pharmaceuticals Inc. Coalition for Epidemic Preparedness Innovations $9.00 1/30/20
Iteos Therapeutics received funding from the Walloon Region to support the clinical development of its two cancer drug programs targeting mechanisms of immunosuppression Iteos Therapeutics SA Walloon Region of Belgium Government $19.65 1/30/20
Swedish Foundations to award Karolinska funding to develop pathways and therapies for Alagille syndrome Karolinska Institutet Swedish Foundations' Starting Grant Payment unspecified 1/17/20
Crohn's & Colitis Foundation to award Koutif Therapeutics' funding to develop KT-1002 for Crohn's disease Koutif Therapeutics Crohn's & Colitis Foundation of America $0.25 1/3/20
ALS Association to award Massachusetts General Hospital funding for first platform amyotrophic lateral sclerosis trial Massachusetts General Hospital ALS Association $3.00 1/14/20
BARDA began procuring the bromelain gel product Nexobrid for emergency stockpile as a medical countermeasure to treat mass casualty emergencies involving thermal burns Mediwound Ltd. U.S. Biomedical Advanced Research and Development Authority $16.50 1/6/20
NIH to award Microcures funding for development of siFi2 against wound healing Microcures Inc. National Institute of Health $1.75 1/13/20
CEPI to award Moderna funding to develop an mRNA vaccine against the coronavirus (2019-nCoV) Moderna Therapeutics Inc. Coalition for Epidemic Preparedness Innovations Payment unspecified 1/23/20
SBRI Healthcare to award Mogrify funding to advance regenerative cartilage therapy to the clinical against osteoarthritis Mogrify Ltd. SBRI Healthcare $1.10 1/29/20
Taiho Oncology to award NCCN funding to evaluate futibatinib against malignancies with FGFR 1-4 aberrations National Comprehensive Cancer Network Taiho Oncology Inc. $2.00 1/27/20
Source Research Foundation to award NYU Langone funding to study the antianxiety and antidepressant effects of psilocybin on cancer-related psychiatric distress NYU Langone Health Source Research Foundation Payment unspecified 1/28/20
NBTS to award Oncoceutics funding to support phase II clinical trial of ONC-201 for EGFR-independent high-grade gliomas Oncoceutics Inc. National Brain Tumor Society $0.20 1/27/20
BIRD to award Oncohost funding to determine and advance the development of personalized cancer therapies Oncohost Ltd. Binational Industrial Research and Development Foundation $1.00 1/21/20
PDC*Line Pharma SA received loans and grants from the Walloon region of Belgium for development of PDC*lung-01 for metastatic lung cancer PDC*Line Pharma SA Walloon region of Belgium $6.58 1/22/20
National Cancer Institute to award Radiomedix funding to develop 212Pb-Alphamedix for the targeted alpha-emitter therapy of neuroendocrine tumors Radiomedix Inc. National Cancer Institute $2.00 1/6/20
BMGF to award Scripps Research funding to develop therapies for tuberculosis, malaria, and other global health challenges Scripps Research Institute Bill & Melinda Gates Foundation $50.00 1/29/20
BARDA to award Summit Therapeutics funding to develop Ridinilazole against Clostridium difficile infection Summit Therapeutics plc Biomedical Advanced Research and Development Authority $8.80 1/23/20
CARB-X to award Taxis funding to develop efflux pump inhibitors for multi-drug-resistant Pseudomonas aeruginosa bacteria Taxis Pharmaceuticals Inc. Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator $14.60 1/8/20
Theraly Fibrosis received funding from the NIH to support a phase II study for developing TLY-012 for treating chronic pancreatitis Theraly Fibrosis Inc. National Institutes of Health $3.90 1/30/20
NHC to fund TOT Biopharm funding to develop TAB-014 for the treatment of wet macular degeneration TOT Biopharm Co. Ltd. National Health Commission Payment unspecified 1/2/20
CARB-X to award Trellis Bioscience funding to manufacture monoclonal antibody for bacterial infections Trellis Bioscience Inc. Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator $7.00 1/14/20
Bill & Melinda to award University of Dundee funding to identify the treatment options for tuberculosis University of Dundee Bill & Melinda Gates Foundation $3.00 1/13/20
ACGT to award University of Pennsylvania funding to improve CAR T-cell clinical trial in prostate cancer University of Pennsylvania Alliance for Cancer Gene Therapy $0.50 1/30/20
NIAID to award University of Wisconsin-Madison funding to develop antibody therapeutics for HIV infection University of Wisconsin-Madison National Institute of Allergy and Infectious Diseases $0.68 1/15/20
NINDS to award Weill Medical College funding to develop new HCN1-selective small molecule inhibitors for treatment of neuropathic pain Weill Medical College of Cornell University National Institute of Neurological Disorders and Stroke $1.76 1/13/20

No Comments